Fellow Stakeholders, As we move into summer, I want to relay some meaningful industry updates and share our progress on our commercialization strategy. As you may know, the U.S. Drug Enforcement Administration (DEA) recently proposed to reclassify marijuana from Schedule I to Schedule III.  We at IGC Pharma welcome the proposal, as this potential reclassification … Continue reading Desk of CEO Marijuana Reclass